IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma
Glioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dio...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | English |
| Publicado: |
MDPI AG
2024-06-01
|
| Colección: | Pharmaceutics |
| Materias: | |
| Acceso en línea: | https://www.mdpi.com/1999-4923/16/7/870 |
| _version_ | 1827177414750371840 |
|---|---|
| author | Zikang Xing Xuewen Li Zhen Ning Tony He Xin Fang Heng Liang Chunxiang Kuang Aiying Li Qing Yang |
| author_facet | Zikang Xing Xuewen Li Zhen Ning Tony He Xin Fang Heng Liang Chunxiang Kuang Aiying Li Qing Yang |
| author_sort | Zikang Xing |
| collection | DOAJ |
| description | Glioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dioxygenase 1 (IDO1), while IDO1 has also been suggested to be related to tumor angiogenesis. Herein, we aim to clarify the potential role of IDO1 in glioma angiogenesis and the mechanism behind it. Bioinformatic analyses showed that the expressions of IDO1 and angiogenesis markers VEGFA and CD34 were positively correlated and increased with pathological grade in glioma. IDO1-overexpression-derived-tryptophan depletion activated the general control nonderepressible 2 (GCN2) pathway and upregulated VEGFA in glioma cells. The tube formation ability of angiogenesis model cells could be inhibited by IDO1 inhibitors and influenced by the activity and expression of IDO1 in condition medium. A significant increase in serum VEGFA concentration and tumor CD34 expression was observed in IDO1-overexpressing GL261 subcutaneous glioma-bearing mice. IDO1 inhibitor RY103 showed positive anti-tumor efficacy, including the anti-angiogenesis effect and upregulation of natural killer cells in GL261 glioma-bearing mice. As expected, the combination of RY103 and anti-angiogenesis agent sunitinib was proved to be a better therapeutic strategy than either monotherapy. |
| first_indexed | 2025-03-21T04:42:51Z |
| format | Article |
| id | doaj.art-f58de9b76c954ec8994599f3b51a2f3f |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2025-03-21T04:42:51Z |
| publishDate | 2024-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-f58de9b76c954ec8994599f3b51a2f3f2024-07-26T12:58:34ZengMDPI AGPharmaceutics1999-49232024-06-0116787010.3390/pharmaceutics16070870IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in GlioblastomaZikang Xing0Xuewen Li1Zhen Ning Tony He2Xin Fang3Heng Liang4Chunxiang Kuang5Aiying Li6Qing Yang7State Key Laboratory of Genetic Engineering, School of Life Sciences, MOE Engineering Research Center of Gene Technology, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Songhu Road 2005, Shanghai 200438, ChinaState Key Laboratory of Genetic Engineering, School of Life Sciences, MOE Engineering Research Center of Gene Technology, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Songhu Road 2005, Shanghai 200438, ChinaState Key Laboratory of Genetic Engineering, School of Life Sciences, MOE Engineering Research Center of Gene Technology, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Songhu Road 2005, Shanghai 200438, ChinaState Key Laboratory of Genetic Engineering, School of Life Sciences, MOE Engineering Research Center of Gene Technology, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Songhu Road 2005, Shanghai 200438, ChinaState Key Laboratory of Genetic Engineering, School of Life Sciences, MOE Engineering Research Center of Gene Technology, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Songhu Road 2005, Shanghai 200438, ChinaShanghai Key Lab of Chemical Assessment and Sustainability, School of Chemical Science and Engineering, Tongji University, Siping Road 1239, Shanghai 200092, ChinaHelmholtz International Lab for Anti-Infectives, Shandong University-Helmholtz Institute of Biotechnology, State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, ChinaState Key Laboratory of Genetic Engineering, School of Life Sciences, MOE Engineering Research Center of Gene Technology, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Songhu Road 2005, Shanghai 200438, ChinaGlioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dioxygenase 1 (IDO1), while IDO1 has also been suggested to be related to tumor angiogenesis. Herein, we aim to clarify the potential role of IDO1 in glioma angiogenesis and the mechanism behind it. Bioinformatic analyses showed that the expressions of IDO1 and angiogenesis markers VEGFA and CD34 were positively correlated and increased with pathological grade in glioma. IDO1-overexpression-derived-tryptophan depletion activated the general control nonderepressible 2 (GCN2) pathway and upregulated VEGFA in glioma cells. The tube formation ability of angiogenesis model cells could be inhibited by IDO1 inhibitors and influenced by the activity and expression of IDO1 in condition medium. A significant increase in serum VEGFA concentration and tumor CD34 expression was observed in IDO1-overexpressing GL261 subcutaneous glioma-bearing mice. IDO1 inhibitor RY103 showed positive anti-tumor efficacy, including the anti-angiogenesis effect and upregulation of natural killer cells in GL261 glioma-bearing mice. As expected, the combination of RY103 and anti-angiogenesis agent sunitinib was proved to be a better therapeutic strategy than either monotherapy.https://www.mdpi.com/1999-4923/16/7/870gliomaangiogenesisindoleamine 2,3-dioxygenase 1tryptophan depletiongeneral control nonderepressible 2 |
| spellingShingle | Zikang Xing Xuewen Li Zhen Ning Tony He Xin Fang Heng Liang Chunxiang Kuang Aiying Li Qing Yang IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma Pharmaceutics glioma angiogenesis indoleamine 2,3-dioxygenase 1 tryptophan depletion general control nonderepressible 2 |
| title | IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma |
| title_full | IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma |
| title_fullStr | IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma |
| title_full_unstemmed | IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma |
| title_short | IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma |
| title_sort | ido1 inhibitor ry103 suppresses trp gcn2 mediated angiogenesis and counters immunosuppression in glioblastoma |
| topic | glioma angiogenesis indoleamine 2,3-dioxygenase 1 tryptophan depletion general control nonderepressible 2 |
| url | https://www.mdpi.com/1999-4923/16/7/870 |
| work_keys_str_mv | AT zikangxing ido1inhibitorry103suppressestrpgcn2mediatedangiogenesisandcountersimmunosuppressioninglioblastoma AT xuewenli ido1inhibitorry103suppressestrpgcn2mediatedangiogenesisandcountersimmunosuppressioninglioblastoma AT zhenningtonyhe ido1inhibitorry103suppressestrpgcn2mediatedangiogenesisandcountersimmunosuppressioninglioblastoma AT xinfang ido1inhibitorry103suppressestrpgcn2mediatedangiogenesisandcountersimmunosuppressioninglioblastoma AT hengliang ido1inhibitorry103suppressestrpgcn2mediatedangiogenesisandcountersimmunosuppressioninglioblastoma AT chunxiangkuang ido1inhibitorry103suppressestrpgcn2mediatedangiogenesisandcountersimmunosuppressioninglioblastoma AT aiyingli ido1inhibitorry103suppressestrpgcn2mediatedangiogenesisandcountersimmunosuppressioninglioblastoma AT qingyang ido1inhibitorry103suppressestrpgcn2mediatedangiogenesisandcountersimmunosuppressioninglioblastoma |